Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Palliation
Is it appropriate to offer combination lung SBRT and immunotherapy for oligometastatic melanoma outside of a clinical trial?
If so, can these be administered concurrently?
Related Questions
Is there a role for radiation in palliating malignant small bowel obstruction?
Would you offer SRS to a hippocampal metastasis in a patient with ES-SCLC treated with prior WBRT?
How would you manage a patient with a high-risk asymptomatic bone metastasis with a driver mutation?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Is it safe to re-irradiate non-spine bone metastases with SBRT if they received previous SBRT?
Do you use a comprehensive volumetric, rather than numeric, cutoff in consideration of SRS vs WBRT for brain metastases?
What normal tissue dose constraints do you use when delivering up to 3 cycles of the palliative quad shot regimen for gynecologic pelvic malignancies?
Would you consider spine re-irradiation after Pluvicto?
Do you have a 15 fraction constraint for the LADA?
Would you offer 12-16 Gy in a single fraction for a symptomatic, non-vertebral bone metastasis?